Biotech Mergers and Acquisitions
It might be only Tuesday, but there have been four major biotech mergers this week worth noting. The entire industry has been the subject of much debate whether or not it is bubbling into an eventual let down for investors. Citi, last week wrote a compelling piece for why this may be true, and eventually concluded that biotech was still a safe bet for those interested. While that issue may still be up in the air, four companies are combining within the category which keeps confidence high for the sector.
Horizon Pharma is set to buy all the outstanding shares of Hyperion Therapeutics in a cash deal valued at $1.1 billion of $46 a share. What will it bring to Horizon? An addition to their portfolio with complementary orphan disease products.
Cellular Dynamics International is set to be acquired by FujiFilm Holdings for $307 million or $16.50 a share. Last year their revenue totalled $16.7 million. The company is a leader in the area of human cellular production with specifications of any precision. Pre-market trading saw a spike around 111%.
Teva Pharmaceuticals has announced it will be acquiring Auspex Pharmaceuticals to the tune of $101 per share in a cash deal. Teva will look to improve their foothold in the movement disorder industry, where they had no position previously. Auspex is a company which specializes in central nervous research.
UnitedHealth will plan to acquire Catamaran Corp with its pharmacy division to create a stronger, new competitor in the market. The deal is structured around a cash buyout with a price tag of $61.50 per share.
To read the original article, click here.Share: